Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

No reduction in gvhd risk for aplastic anemia patients to combined third-party unrelated cord blood in haploidentical hematopoietic stem cells transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

WZWei ZhaoXCXingyu CaoDLDeyan Liu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows no change in graft-versus-host disease risk in aplastic anemia with third-party infusion.

Key Points

  • To evaluate the efficacy and safety of third-party cell infusion during haploidentical allo-HSCT in aplastic anemia patients.
  • Retrospectively analyzed 251 aplastic anemia patients undergoing haplo allo-HSCT from 2012-2024
  • Patients divided into haplo-cord and haplo cohorts based on third-party UCB use
  • Conditions and outcomes of both cohorts compared, focusing on GVHD and survival rates.
  • No significant difference in rates of graft-versus-host disease between haplo cohort and haplo-cord cohort
  • 5-year overall survival rates were similar at 80% for haplo and 76.8% for haplo-cord
  • ATG formulation associated with increased risk of EBV reactivation.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e523https://doi.org/10.1182/blood-2025-2495
View Full Paper
Ask AI
Bookmark
Share